Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW685698 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GW685698 | DRUG | - |
Inclusion criteria: * Informed consent. * Outpatient. * Diagnosis of perennial allergic rhinitis with symptoms. * Able to comply with study procedures. Exclusion criteria: * Significant concomitant medical condition. * Use of corticosteroids/allergy medications. * Laboratory abnormality. * Positi...
GW685698 is an investigational small molecule being developed by GSK plc for respiratory conditions. It is also known as fluticasone furoate. Clinical studies have evaluated it in allergic rhinitis, chronic obstructive pulmonary disease, and asthma.
GW685698 has been studied for use in seasonal allergic rhinitis, chronic obstructive pulmonary disease, and asthma. Clinical trials have assessed its efficacy and safety in these respiratory conditions.
GW685698 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK.
GW685698 has been evaluated in Phase 3 clinical trials for allergic rhinitis and asthma, and in a Phase 2 trial for chronic obstructive pulmonary disease. All trials listed are completed, and the drug remains investigational.
GW685698 has been studied in completed clinical trials including NCT00358475 for perennial allergic rhinitis, NCT00731822 for chronic obstructive pulmonary disease, and NCT01498653 for asthma in Asian ancestry subjects.
Yes, GW685698 is also known as fluticasone furoate. In clinical trials, it has been studied alone and in combination with vilanterol trifenatate for respiratory conditions.